Regeneron's Antibody Cocktail Offers Long-Term Protection Against COVID-19
11/09/2021
Regeneron Pharmaceuticals said Monday that a single dose of the antibody cocktail REGEN-COV (casirivimab and imdevimab) reduced the risk of contracting COVID-19 by 81.6% in the two- to eight-month period after it was given. The result is in line with an earlier analysis from the Phase III trial showing that REGEN-COV cut the risk by 81.4% in the first month after dosing, according to a FirstWord Pharma report.
"These data add to the increasing body of evidence supporting use of REGEN-COV to prevent COVID-19 in uninfected individuals," remarked chief scientific officer George Yancopoulos, adding that this "may be especially useful for the many immunocompromised people who do not respond adequately to vaccines."